Cross Reactive Material 197 glycoconjugate vaccines contain privileged conjugation sites

Production of glycoconjugate vaccines involves the chemical conjugation of glycans to an immunogenic carrier protein such as Cross-Reactive-Material-197 (CRM(197)). Instead of using glycans from natural sources recent vaccine development has been focusing on the use of synthetically defined minimal...

Descripción completa

Detalles Bibliográficos
Autores principales: Möginger, Uwe, Resemann, Anja, Martin, Christopher E., Parameswarappa, Sharavathi, Govindan, Subramanian, Wamhoff, Eike-Christian, Broecker, Felix, Suckau, Detlev, Pereira, Claney Lebev, Anish, Chakkumkal, Seeberger, Peter H., Kolarich, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4740906/
https://www.ncbi.nlm.nih.gov/pubmed/26841683
http://dx.doi.org/10.1038/srep20488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4740906/
https://www.ncbi.nlm.nih.gov/pubmed/26841683
http://dx.doi.org/10.1038/srep20488

Ejemplares similares